Atf7ip is a negative regulator of bone morphogenetic protein 2 promoting osteogenic differentiation in mouse embryonic adult cells

doi:10.12307/2024.716

Abstract

Abstract: BACKGROUND: Whether activating transcription factor 7 interacting protein (Atf7ip) is involved in the regulation in osteogenic differentiation is still controversial, and studying its impact on osteogenic differentiation and its specific mechanisms is of great significance.
OBJECTIVE: To investigate the effect of Atf7ip on bone morphogenetic protein 2 promoting osteogenic differentiation of mouse embryonic osteoblast precursor cells (MC3T3-E1).
METHODS: MC3T3-E1 cells cultured in vitro were divided into three groups: normal group, interference group (NC-siRNA group, Atf7ip-siRNA group), and high expression group (CMV-VC group and CMV-Atf7ip group), and were transfected for 24 hours, and then treated with 200 ng/mL bone morphogenetic protein 2 for 0, 12, 24, and 48 hours, respectively. qRT-PCR was used to detect the mRNA expression levels of Atf7ip, alkaline phosphatase, osteocalcin, type I collagen α1 in the cells of each group. Western blot assay was used to detect the protein expression of osteogenic differentiation markers Sp7 and Runx2, and the expression of Atf7ip binding molecule SETDB1, histone H3 and H3K9me3. Alkaline phosphatase activity was detected by alkaline phosphatase staining.
RESULTS AND CONCLUSION: (1) With the increase of bone morphogenetic protein 2 treatment time, the protein and mRNA expression of Atf7ip decreased, while the protein expression of Sp7, Runx2 and the mRNA expression of osteocalcin and alkaline phosphatase increased significantly (P < 0.05). There was no significant change in the protein expression of Atf7ip binding molecule SETDB1. (2) Compared with the NC-siRNA group, the protein expression of Sp7, Runx2 and the mRNA expression of osteocalcin and type I collagen α1 were significantly up-regulated (P < 0.05), and alkaline phosphatase activity was significantly enhanced; and H3K9 methylation significantly decreased in the Atf7ip-siRNA group (P < 0.05). (3) Compared with the CMV-VC group, the protein expression of Sp7 and Runx, as well as mRNA expression of osteocalcin, alkaline phosphatase, and type I collagen α1 was significantly downregulated (P < 0.05), and the alkaline phosphatase activity was significantly reduced in the CMV-Atf7ip group, while the H3K9 methylation protein in the CMV-Atf7ip group was significantly upregulated compared to the control group (P < 0.05). (4) In conclusion, Atf7ip expression was decreased during bone morphogenetic protein 2-induced osteogenic differentiation of MC3T3-E1, and osteogenic differentiation was significantly increased after knockdown of Atf7ip. Overexpression of Atf7ip significantly weakened osteogenic differentiation, indicating that Atf7ip is a negative regulatory factor of bone morphogenetic protein 2 promoting osteogenic differentiation of MC3T3-E1 cells.

Key words: MC3T3-E1, Atf7ip, bone morphogenetic protein 2, osteogenic differentiation, H3, H3K9me3

CLC Number:

Shi Xian, Han Chunqing, Hu Anran, Kuang Shuyun, Ran Yimeng, Wu Yu. Atf7ip is a negative regulator of bone morphogenetic protein 2 promoting osteogenic differentiation in mouse embryonic adult cells[J]. Chinese Journal of Tissue Engineering Research, 2024, 28(31): 4931-4936.

Figures/Tables 3

References

[1] 中华医学会骨质疏松和骨矿盐疾病分会,章振林.原发性骨质疏松症诊疗指南(2022)[J].中国全科医学,2023,26(14):1671-1691.
[2] 周倩,杨胜慧.积极应对人口老龄化政策背景下我国老年人口健康状况分析——基于第六次、第七次全国人口普查数据的比较分析[J].人口与健康,2023(7):49-53.
[3] WANG W, MAO J, CHEN Y, et al. Naringin promotes osteogenesis and ameliorates osteoporosis development by targeting JAK2/STAT3 signalling. Clin Exp Pharmacol Physiol. 2022;49(1):113-121.
[4] ANAGNOSTIS P, PASCHOU SA, MINTZIORI G, et al. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas. 2017;101:23-30.
[5] 刘晖,李熙,吴学军,等.miR-21通过调节TGF-β/activin信号通路影响人骨髓间质干细胞向成骨细胞分化的机制[J].中国老年学杂志,2023,43(5):1211-1214.
[6] HOJO H, SAITO T, HE X, et al. Runx2 regulates chromatin accessibility to direct the osteoblast program at neonatal stages. Cell Rep. 2022; 40(10):111315.
[7] MORGAN MAJ, SHILATIFARD A. Reevaluating the roles of histone-modifying enzymes and their associated chromatin modifications in transcriptional regulation. Nat Genet. 2020;52(12):1271-1281.
[8] GOU LT, LIM DH, MA W, et al. Initiation of Parental Genome Reprogramming in Fertilized Oocyte by Splicing Kinase SRPK1-Catalyzed Protamine Phosphorylation. Cell. 2020;180(6):1212-1227.e14.
[9] WU J, LI J, CHEN K, et al. Atf7ip and SETDB1 interaction orchestrates the hematopoietic stem and progenitor cell state with diverse lineage differentiation. Proc Natl Acad Sci U S A. 2023;120(1):e2209062120.
[10] SIN JH, ZUCKERMAN C, CORTEZ JT, et al. The epigenetic regulator ATF7ip inhibits Il2 expression, regulating Th17 responses. J Exp Med. 2019;216(9):2024-2037.
[11] TANJAYA J, HA P, ZHANG Y, et al. Genetic and pharmacologic suppression of PPARγ enhances NELL-1-stimulated bone regeneration. Biomaterials. 2022;287:121609.
[12] YANG P, TRONCONE L, AUGUR ZM, et al. The role of bone morphogenetic protein signaling in vascular calcification. Bone. 2020; 141:115542.
[13] CHEN Y, ZHAO X, WU H. Transcriptional Programming in Arteriosclerotic Disease: A Multifaceted Function of the Runx2 (Runt-Related Transcription Factor 2). Arterioscler Thromb Vasc Biol. 2021;41(1): 20-34.
[14] HU G, SHI X, QU X, et al. Atf7ip Inhibits Osteoblast Differentiation via Negative Regulation of the Sp7 Transcription Factor. Int J Mol Sci. 2023;24(5):4305.
[15] QASEEM A, HICKS LA, ETXEANDIA-IKOBALTZETA I, et al. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians. Ann Intern Med. 2023;176(2):224-238.
[16] BEREBICHEZ-FRIDMAN R, MONTERO-OLVERA PR. Sources and Clinical Applications of Mesenchymal Stem Cells: State-of-the-art review. Sultan Qaboos Univ Med J. 2018;18(3):e264-e277.
[17] IZUMIYA M, HANIU M, UEDA K, et al. Evaluation of MC3T3-E1 Cell Osteogenesis in Different Cell Culture Media. Int J Mol Sci. 2021;22(14): 7752.
[18] 刘晖,李熙,吴学军,等.miR-21通过调节TGF-β/activin信号通路影响人骨髓间质干细胞向成骨细胞分化的机制[J].中国老年学杂志,2023,43(5):1211-1214.
[19] ZHANG L, XU L, ZHANG X, et al. Methyltransferase SETDB1 Promotes Osteoblast Proliferation by Epigenetically Silencing Macrod2 with the Assistance of Atf7ip. Cells. 2022;11(16):2580.
[20] FIDDES IT, LODEWIJK GA, MOORING M, et al. Human-Specific NOTCH2NL Genes Affect Notch Signaling and Cortical Neurogenesis. Cell. 2018;173(6):1356-1369.e22.
[21] CARBALLO GB, HONORATO JR, DE LOPES GPF, et al. A highlight on Sonic hedgehog pathway. Cell Commun Signal. 2018;16(1):11.
[22] 安小宁. PNS介导BMP-Smad信号通路调控BMSCs成骨分化的机制研究[D].南宁:广西医科大学,2019.
[23] OH WT, YANG YS, XIE J, et al. WNT-modulating gene silencers as a gene therapy for osteoporosis, bone fracture, and critical-sized bone defects. Mol Ther. 2023;31(2):435-453.
[24] PARK I, HWANG YJ, KIM T, et al. In silico probing and biological evaluation of SETDB1/ESET-targeted novel compounds that reduce tri-methylated histone H3K9 (H3K9me3) level. J Comput Aided Mol Des. 2017;31(10):877-889.
[25] GUO Y, MAO X, XIONG L, et al. Structure-Guided Discovery of a Potent and Selective Cell-Active Inhibitor of SETDB1 Tudor Domain. Angew Chem Int Ed Engl. 2021;60(16):8760-8765.